Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS ViiV Supporting Campaigns to Raise HIV Diagnosis Rate in Japan: CEO
June 24, 2019
-
REGULATORY Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
-
TRENDS 12 Foreign Drug Makers Eke Out 1.2% Growth in Japan, but Stagnation Lingers
June 21, 2019
-
REGULATORY MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
-
REGULATORY Japan Approves Roche/Chugai’s Tumor-Agnostic Rozlytrek, Alnylam’s RNAi Drug and More
June 19, 2019
-
TRENDS Foreign Pharmas Creating Environments to Empower Women, Making Headway for Sales Reps Too
June 18, 2019
-
ORGANIZATION Fix Price Maintenance Premium to Make It Fit Its Concept, Revisit Product/Company Criteria: FPMAJ
June 17, 2019
-
BUSINESS Japanese Drug Makers Beefing Up China Biz amid Regulatory Tailwind
June 14, 2019
-
REGULATORY Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
June 13, 2019
-
BUSINESS Rakuten Medical Could File Photoimmunotherapy for Head and Neck Cancer in 2022; COO Says More Indications Eyed
June 12, 2019
-
BUSINESS Japan Ethical Drug Sales Shrivel, but Many Beat Conservative Guidance
June 11, 2019
-
REGULATORY MHLW Study Group Drafting Guidelines for New Dyslipidemia Drug Development, First in 30 Years
June 11, 2019
-
BUSINESS Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
-
BUSINESS Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
-
ORGANIZATION Doctors’ Lobby Voices Opposition to Changing Health Coverage, Copay Rates for Minor Illnesses
June 6, 2019
-
ORGANIZATION Ahead of G20 Summit, Global Pharma Leaders Prod PM Abe to Take Leadership in Addressing Health Challenges
June 5, 2019
-
REGULATORY Reborn PMDA Boots Up under New Skipper, Bolstering “Patient First” Initiatives
June 4, 2019
-
BUSINESS Biogen to Leverage Aducanumab Learnings, Spinraza to Remain Foundation of SMA Care: Japan Chief
June 3, 2019
-
REGULATORY June Approval Likely for Chugai’s NTRK-Gene Targeting Entrectinib, 2nd Tumor-Agnostic Drug
May 31, 2019
-
REGULATORY LDP Junior Politicians Set Up Vaccine Study Group
May 31, 2019
ページ
The female manager ratio at foreign drug makers in Japan has been on the steady rise since the enforcement in April 2016 of the Act on Promotion of Women’s Participation and Career Advancement in the Workplace. Women now account for…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Earlier this year, I attended a conference discussing the trends of Japan’s pharmaceutical industry. The objective of the conference was to determine what Japanese pharmaceutical companies were doing, and what they could be doing, to make themselves more competitive on…